BD CEO Tom Polen Addresses FDA 510(k) Clearance of BD Alaris™ Infusion System
FRANKLIN LAKES, N.J., July 24, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) Chairman, CEO and President Tom Polen issued the following message regarding the U.S. Food and Drug Administration (FDA) 510(k) clearance for the updated BD Alaris™ Infusion System :
- FRANKLIN LAKES, N.J., July 24, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) Chairman, CEO and President Tom Polen issued the following message regarding the U.S. Food and Drug Administration (FDA) 510(k) clearance for the updated BD Alaris™ Infusion System :
"Hello, I'm Tom Polen, chairman, CEO and president of BD. - I'm very pleased to announce that we have reached the important milestone of obtaining FDA 510(k) clearance of the updated BD Alaris™ Infusion System.
- Everyone at BD is grateful for the support and patience that our customers afforded us through the 510(k) submission and review process.
- The updated Alaris System addresses all open recalls, with the latest hardware, a new version of software, and important cybersecurity updates.